Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.
Moleculin Biotech (MBRX) has received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 ...
Clinical Trials Arena on MSN2d
Moleculin Biotech gains approval for enrolment in trial of AML therapy in UkraineUS-based pharmaceutical company Moleculin Biotech has received approval from Ukraine's Ministry of Health to begin enrolment in its Phase III trial of annamycin with cytarabine for treating acute ...
LOWELL, Mass. (AP) — Aerin Frankel denied the New York Sirens on four straight penalty shots and the Boston Fleet earned a 3-2 shootout win on Friday night. The Boston goalkeeper made 25 saves ...
The good news for the Fleet is they have goaltender Aerin Frankel. The former Patty Kazmaier Award winner at Northeastern denied four Sirens chances — disrupting two of the bids before a shot ...
LOWELL — After suffering a pair of two-goal losses to the Toronto Sceptres this season, the Boston Fleet got their revenge on Wednesday night. Boston scored twice in the first period and held on ...
Copyright 2025 The Associated Press. All Rights Reserved. Share LOWELL, Mass. (AP) — Alina Müller and Emily Brown each scored their first goal of the season in the ...
Key recommendations for policymakers and businesses. Jan 22, 2025 21:57 JSW UAV to Set Up Rs 800 Crore Facility in Telangana JSW UAV Ltd. has signed an MoU with the Telangana government to establish a ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...
Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback